Kaleen N. Hayes

Feb 14, 2025 | onlinelibrary.wiley.com | Meghan A. Cupp |Kaleen N. Hayes |Sarah Berry |Francesca L. Beaudoin

Andrew R. Zullo Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island, USA Center of Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA Department of Pharmacy, Rhode Island Hospital, Providence, Rhode Island, USASearch for more papers by this author

Dec 5, 2023 | agsjournals.onlinelibrary.wiley.com | Sarah Berry |Kaleen N. Hayes |Yoojin Lee |Yuan Zhang

CONFLICT OF INTEREST STATEMENT Andrew R. Zullo has received funding from Sanofi paid directly to Brown University for collaborative research on the epidemiology of infections and vaccinations in nursing home residents. Sarah D. Berry and Douglas P. Kiel receive royalties from Wolters-Klewer related to chapters on falls. No other authors have any conflicts of interest with this analysis.

Aug 2, 2023 | jamanetwork.com | Daniel Harris |Kaleen N. Hayes |Andrew R. Zullo

Key PointsQuestion  Are there safety differences between mRNA vaccines for COVID-19, and do those differences vary by frailty level? Findings  In this cohort study of 6 388 196 older US adults, a 4% lower risk of pulmonary embolism, a 2% lower risk of thromboembolic events, and a 14% lower risk of diagnosed COVID-19 were observed among those who received the mRNA-1273 vaccine compared with the BNT162b2 vaccine.